AZ’s Oncology R&D Head On China’s Scientific Promise And True Innovation

UK Major Committed To R&D Presence, Alliances

AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.

AstraZeneca’s 14 years of deal-making in China could be traced to true innovations. (Shutterstock)

More from China

More from Deals